World Health Organization statistics identify 150 million people with diabetes mellitus worldwide and suggest that this figure may double by 2025. In countries with a western lifestyle, the number of patients admitted for renal replacement therapy with diabetes as a co-morbid condition has increased significantly up to three to four times in a period of 10 years. Diabetes and renal failure are thus tightly linked diseases, and so is anemia. However, whether anemia may be worsened and/or directly, at least in part, caused by diabetes is not clearly elucidated yet. In this article, we review the prevalence, pathophysiology and consequences of anemia in diabetic patients.

Keywords:
Anemia, Diabetes, Erythropoietin, Hemoglobin, Renal failure
1.
Ritz E, Rychlik I, Locatelli F, Halimi S: End stage renal failure in type 2 diabetes: A medical catastrophe of worldwide/ dimensions. Am J Kidney Dis 1999;34:795–808.
2.
Chantrel F, Enache I, Boullier M, et al: Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 1999;14:129–136.
3.
Bosman D, Winkler A, Marsden J, et al: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001;24:495–499.
4.
Inomata S, Itoh M, Imai H, Sato T: Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 1997;75:426–430.
5.
Ishimura E, Okumo S, et al: Diabetes mellitus increases the severity of anemia in non dialyzed patients with renal failure. J Nephrol 1998;11:83–86.
6.
Dikow R, Schwenger V, Schömig M, Ritz E: How should we manage anemia in patients with diabetes? Nephrol Dial Transplant 2002;17(S):67–72.
7.
Kazmi WH, Annamaria TK, Khan S, Abichandan I, Ruthazer R, Obrador G, Pereira BJG: Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803–812.
8.
Valderrabano F, Hörl WH, MacDougall IC, Rossert J, Rutowski B, Wauters JP: Pre-dialysis survey on anemia management. Nephrol Dial Transplant, 2003;18:89–100.
9.
Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P: Incidence of anemia, and use of epoetin therapy in pre-dialysis patients: A prospective study in 403 patients. Nephrol Dial Transplant 2002;17:1621–1627.
10.
Thomas CM, MacIsaac RJ, Tsalamandris C, Power D, Jerums G: Unrecognized anemia in patients with diabetes. Diabetes Care 2003;26:1164–1169.
11.
Astor BC, Muntner P, Levin A, Eristace JA, Coresh J: Association of kidney function with anemia: the third national health and nutrition examination survey (1988–1994). Arch Intern Med 2002;162:1401–1408.
12.
Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Gombina I, Fulchez G, Yve D, Jerums G: The Burden of anemia in type 2 diabetes and the role of nephropathy: A cross-sectional study. Nephrol Dial Transpl 2004;19:1792–1797.
13.
Stevens PE, Didonoghue DJ, Lameire NR: Anemia in patients with diabetics: Unrecognized, undetected and untreated; Curr Med Res Op 200;19:395–401.
14.
Takaku F, Hirasima K, Okinaka S: Effects of the bilateral section of the splanchnic nerve in erythropoiesis. Nature 1961;191:500–501.
15.
Beynon G: The influence of the autonomic nervous system in the control of the erythropoietin secretion in the hypoxic rat. J Physiol 1977;266:347–360.
16.
Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ: Erythropoietin depletion and anemia in diabetes mellitus. Diab Med 1999;16:813–819.
17.
Rarick MU, Espina BM, Colley DT, Chrusoki E, Gandara S, Feinstein DI: Treatment of a unique anemia in patients with IDDM with erythropoietin-alpha. Diab Care 1998;21:423–426.
18.
Ricerca BM, Todaro L, Caduto S, Cotroneo P, Damiani P, Manto A, Pitocco D, Storti S, Ghirlanda G: Blunted erythropoietin response to anemia in type 1 diabetic patients disease. Blood 1992;80:1639–1647.
19.
Jeffrey RF, Kendall RG, Prabhu O, Norfolk DR, Will EJ, Davison AM: Re-establishment of erythropoietin responsiveness in end-stage renal failure following renal transplantation. Clin Nephrol 1995;44:241–247.
20.
Means RT, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639–1647.
21.
Donnelly S, Shah BR: Erythropoietin deficiency in hyporeninemia. Am J Kidney Dis 1999;33:947–953.
22.
Bayes B, Serra A, Junca J, Lanzurica R: Successful treatment of anemia of nephritic syndrome with recombinant erythropoietin. Nephrol Dial Transplant 1998;13:1894–1895.
23.
Qiao Q, Keinanen F, Kiukanniemi S, Laara E: The relationship between haemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997;50:153–158.
24.
Davis M, Fisher M, Gangnon R, et al: Risk factors for high risk proliferative retinopathy study report. Invest Ophtalmol Vis Sci 1998;39:233–252.
25.
Shorb S: Anemia and diabetic retinopathy. Am J Ophthalmol 1985;100:434–436.
26.
Friedman E, Brown C, Berman D: Erythropoietin in diabetic macular oedema and renal insufficiency. Am J Kidney Dis 1995;26:202–208.
27.
Barnes AJ, Locke P, Sendder PR, Dormandy TL, Dormangy JA, Slack J: Hyperviscosity: A treatable component of diabetic microcirculatory. Lancet 1977;15:789–902.
28.
Mc Millan DE, utterback NG, Puma JL, Barbara S: Reduced erytrocytes deformability in diabetes. Diabetes 1978;27:895–901.
29.
Sinclair S: Macular retinal capillary hemodynamics in diabetic patients. Ophthalmology 1991;98:1580–1586.
30.
Sinclair S, Mainster M: Diabetic macular edema: New concepts of pathology and treatment (Editorial). Semin Ophthalmol 1999;14:197–199.
31.
Benjamin L: Glucose, VEGF-A and diabetic complications. Am J Pathol 2001;158:1181–1184.
32.
Kuriyama S, Tomonari H, Yoshida H, Hasimoto T, Kawagushi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non diabetic patients. Nephron 1997;77:176–185.
33.
Ueda I, Shoji T, Emoto M, Morioka T, Matsumoto N, Fukumoto S, Miki T, Inaba M, Nishizawa Y: Factors affecting progression of renal failure in patients with type 2 diabetes. Diab Care 2003;26:1530–1534.
34.
Silverberg DS, Wexler D, Blum WD, Tchebiner JZ, Shops D, Keren G, Schwatz D, Baruch R, Yachnin T; Shraked M, Schwartz I, Steinbruch S, Taina A: The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;17:141–146.
35.
Foley RN: Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997;40:1307–1312.
36.
Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelsshon D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjen O: Left ventricular mass index increase in early renal disease: Impact of decline in haemoglobin. Am J Kidney Dis 1999;34:125–134.
37.
Portoles J: Cardiovascular effects of recombinant human erythropoietin in pre-dialysis patients. Am J Kidney Dis 1997;29:541–548.
38.
Hayashi T: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in pre-dialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250–256.
39.
Revised European Best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transpl 2004;19(S2):ii1–ii47.
40.
Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584–590.
41.
Furuland H, Luige T, Alhmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with erythropoietin-alpha in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;28:353–361.
42.
Laville M: New strategies in anemia management. ACORD (Anemia Correction in Diabetes) trial. Acta Diabetol 2004;41(S1):S18–S22.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.